Risto Cel Meets Stated Pivotal Sickle Cell Endpoints

Company Beam Therapeutics Event Type Pivotal interim topline (BEACON) Modality Ex vivo base-edited HSC therapy Asset Ristoglogene autogetemcel (risto-cel) Target HBG1/HBG2 promoters (BCL11A repression site) Disease Area Sickle cell disease Summary Beam said its prespecified BEACON interim analysis met the independently adjudicated endpoint of freedom…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *